Immunobiology of Ebola and Lassa Virus Infections

Overview

Journal Nat Rev Immunol

Specialty Allergy & Immunology

Date 2017 Jan 24

PMID 28111475

Citations 65

Authors

Joseph B Prescott

Andrea Marzi

David Safronetz

Shelly J Robertson

Heinz Feldmann

Sonja M Best

Affiliations

Soon will be listed here.

Abstract

Two of the most important contemporary emerging viruses that affect human health in Africa are Ebola virus (EBOV) and Lassa virus (LASV). The 2013-2016 West African outbreak of EBOV was responsible for more than 11,000 deaths, primarily in Guinea, Sierra Leone and Liberia. LASV is constantly emerging in these and surrounding West African countries, with an estimate of more than 500,000 cases of Lassa fever, and approximately 5,000 deaths, annually. Both EBOV and LASV are zoonotic, and human infection often results in a severe haemorrhagic fever in both cases. However, the contribution of specific immune responses to disease differs between EBOV and LASV. This Review examines innate and adaptive immune responses to these viruses with the goal of delineating responses that are associated with protective versus pathogenic outcomes.

Citing Articles

Innate Immune Response Against Batai Virus, Bunyamwera Virus, and Their Reassortants.

Zoller D, Saurich J, Metzger J, Jung K, Lepenies B, Becker S Viruses. 2025; 16(12.

PMID: 39772143 PMC: 11680289. DOI: 10.3390/v16121833.

Current perspectives on vaccines and therapeutics for Lassa Fever.

Warner B, Safronetz D, Stein D Virol J. 2024; 21(1):320.

PMID: 39702419 PMC: 11657583. DOI: 10.1186/s12985-024-02585-7.

Viral sepsis: diagnosis, clinical features, pathogenesis, and clinical considerations.

Xu J, Zhang W, Fu J, Fang X, Gao C, Li C Mil Med Res. 2024; 11(1):78.

PMID: 39676169 PMC: 11648306. DOI: 10.1186/s40779-024-00581-0.

Quantification of heterogeneity in human CD8 T cell responses to vaccine antigens: an HLA-guided perspective.

Harris D, Shanker A, Montoya M, Llewellyn T, Matuszak A, Lohar A Front Immunol. 2024; 15:1420284.

PMID: 39624092 PMC: 11608996. DOI: 10.3389/fimmu.2024.1420284.

Report of a SPEAC webinar 22 september 2023: Sensorineural hearing loss, lassa virus disease and vaccines.

Reed N, Brewer C, Akintunde G, Blackie F, Charles L, Fast P Vaccine. 2024; 43(Pt 1):126525.

PMID: 39579650 PMC: 11734638. DOI: 10.1016/j.vaccine.2024.126525.

References

Pannetier D, Reynard S, Russier M, Journeaux A, Tordo N, Deubel V . Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus. J Virol. 2011; 85(16):8293-306. PMC: 3147965. DOI: 10.1128/JVI.02120-10. View

Richard A, Zhang A, Park S, Farzan M, Zong M, Choe H . Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses. Proc Natl Acad Sci U S A. 2015; 112(47):14682-7. PMC: 4664333. DOI: 10.1073/pnas.1508095112. View

Bowen M, Peters C, Nichol S . Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts. Mol Phylogenet Evol. 1998; 8(3):301-16. DOI: 10.1006/mpev.1997.0436. View

Hartman A, Towner J, Nichol S . A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology. 2004; 328(2):177-84. DOI: 10.1016/j.virol.2004.07.006. View

Pettitt J, Zeitlin L, Kim D, Working C, Johnson J, Bohorov O . Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med. 2013; 5(199):199ra113. DOI: 10.1126/scitranslmed.3006608. View

Frame J, Baldwin Jr J, Gocke D, Troup J . Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg. 1970; 19(4):670-6. DOI: 10.4269/ajtmh.1970.19.670. View

Mupapa K, Mukundu W, Bwaka M, Kipasa M, de Roo A, Kuvula K . Ebola hemorrhagic fever and pregnancy. J Infect Dis. 1999; 179 Suppl 1:S11-2. DOI: 10.1086/514289. View

Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti J . Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014; 514(7520):47-53. PMC: 4214273. DOI: 10.1038/nature13777. View

Paulsen M, Janssen O . Pro- and anti-apoptotic CD95 signaling in T cells. Cell Commun Signal. 2011; 9:7. PMC: 3090738. DOI: 10.1186/1478-811X-9-7. View

10.

Fiorentino D, Bond M, Mosmann T . Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989; 170(6):2081-95. PMC: 2189521. DOI: 10.1084/jem.170.6.2081. View

11.

Chang T, Kubota T, Matsuoka M, Jones S, Bradfute S, Bray M . Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog. 2009; 5(6):e1000493. PMC: 2696038. DOI: 10.1371/journal.ppat.1000493. View

12.

Mattia J, Vandy M, Chang J, Platt D, Dierberg K, Bausch D . Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect Dis. 2016; 16(3):331-8. PMC: 5617647. DOI: 10.1016/S1473-3099(15)00489-2. View

13.

Villinger F, Rollin P, Brar S, Chikkala N, Winter J, Sundstrom J . Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis. 1999; 179 Suppl 1:S188-91. DOI: 10.1086/514283. View

14.

Luthra P, Ramanan P, Mire C, Weisend C, Tsuda Y, Yen B . Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe. 2013; 14(1):74-84. PMC: 3875338. DOI: 10.1016/j.chom.2013.06.010. View

15.

Leroy E, Baize S, Volchkov V, Fisher-Hoch S, Georges-Courbot M, Capron M . Human asymptomatic Ebola infection and strong inflammatory response. Lancet. 2000; 355(9222):2210-5. DOI: 10.1016/s0140-6736(00)02405-3. View

16.

Feng Z, Cerveny M, Yan Z, He B . The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J Virol. 2006; 81(1):182-92. PMC: 1797262. DOI: 10.1128/JVI.01006-06. View

17.

Carrera Silva E, Chan P, Joannas L, Errasti A, Gagliani N, Bosurgi L . T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response. Immunity. 2013; 39(1):160-70. PMC: 4017237. DOI: 10.1016/j.immuni.2013.06.010. View

18.

Basler C . Innate immune evasion by filoviruses. Virology. 2015; 479-480:122-30. PMC: 4424075. DOI: 10.1016/j.virol.2015.03.030. View

19.

Parren P, Geisbert T, Maruyama T, Jahrling P, Burton D . Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol. 2002; 76(12):6408-12. PMC: 136210. DOI: 10.1128/jvi.76.12.6408-6412.2002. View

20.

Olinger Jr G, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B . Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A. 2012; 109(44):18030-5. PMC: 3497800. DOI: 10.1073/pnas.1213709109. View